(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 May 2010 (27.05.2010)

PCT

(10) International Publication Number
WO 2010/059654 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 35/00* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/US2009/064881

(22) International Filing Date:
18 November 2009 (18.11.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/116,825 21 November 2008 (21.11.2008) US
61/219,903 24 June 2009 (24.06.2009) US

(71) Applicant *(for all designated States except US)*: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **DAVIES, Julian** [GB/US]; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US). **LIU, Ling** [US/US]; Eli Lilly and Company, Lilly Corporate Center, indianapolis, Indiana 46285 (US). **LU, Jirong** [US/US]; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US). **VAILLANCOURT, Peter, Edward** [US/US]; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US). **WORTINGER, Mark, Andrew** [US/US]; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US). **ZENG, Wei** [CA/US]; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(74) Agents: **MARTINEZ, Alejandro** et al.; Eli Lilly and Company, Patent Division, P. O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: c-MET ANTIBODIES

(57) Abstract: Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met.

WO 2010/059654 A1